4ANTMAN K, LAGAKOS S, DRAZEN J. Designing and funding clinical trials of novel therapies [J]. N Engl J Med, 2000, 324 (14): 1207-1238.
5LEVINE AM, TULPULE A. Clinical aspects and management of AIDS-related Kaposi's sarcoma [J]. Eur J Cancer, 2001, 37(10): 1288-1295.
6MARCHISONE C, BENELLI R, ALBINI A,et al. Inhibition of angiogenesis by class I interferons in models of Kaposi's sarcoma [J]. Int J Biol Markers, 1999, 14: 257-262.
2Kinlen L. In immunolgic factors, including AIDS. Sehotterdeld D,Fraumeni JF, eds. Cancer epidemiology and prevention, 2nd edn.New York, Oxford University Press, 1996. 532-545.
3IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human immunodeficiency viruses and human T-cell lymphotropic viruses. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 67. Lyon, IARC, 1996.
4CDC. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR, 1987,36(S-1) : 1.
5CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR, 1993,41(RR-17) : 1.
6Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet,1998,351:1833-1839.
7Biggar RJ, Frisch M, Goedert J J, et al. Risk of cancer in children with AIDS. JAMA,2000,284 : 205 -209.
8Hengge UR, Ruzicka T, Tyring SK, et al. Update on Kaposi's sarcoma and other HI-IV8 associated diseases, part 1 : epidemiology,environmental predispositions, clinical manifestations, and therapy.Lancet Infect Dis, 2002, 2:281-292.
9Eltom MA, Jemal A, Mbulaiteye SM, et al. Trends in Kaposi' s sarcoma and non-Hodgkin' s lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst, 2002, 94:1204-1210.
10Dal Maso L, Serraino D, Franceschi S. Epidemiology of AIDS-related tumors in developed and developing countries. Eur J Cancer,2001,37: 1188-1201.
